Skip to main content
SpringerLink
Log in

ICER issues final reports on esketamine and siponimod

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Comparative Effectiveness Public Advisory Council

References

  1. Institute for Clinical and Economic Review. ICER Issues Final Report and Policy Recommendations on Esketamine for Treatment-Resistant Depression. Internet Document : 20 Jun 2019. Available from: URL: https://icer-review.org/announcements/trd_final_report/

  2. Institute for Clinical and Economic Review. ICER Issues Final Report and Policy Recommendations on Siponimod for Secondary Progressive Multiple Sclerosis. Internet Document : 20 Jun 2019. Available from: URL: https://icer-review.org/announcements/spms_final_report/

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ICER issues final reports on esketamine and siponimod. PharmacoEcon Outcomes News 831, 3 (2019). https://doi.org/10.1007/s40274-019-5991-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-5991-6

Search

Navigation